Evidence map›Paper›PMID 38193707›Full record

ArticlemSystems2024

The microbial metabolite urolithin A reduces

Sweta Ghosh, Daniel Erickson, Michelle J Chua, James Collins, Venkatakrishna Rao Jala

Open access · goldAbstract read
In one paragraph

Article in mSystems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Mechanisms ofFrontiers in cellular and infection microbiology · 2025
    Review
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sweta GhoshDepartment of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, USA.
Daniel EricksonDepartment of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, USA.
Michelle J ChuaDepartment of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, USA.
James CollinsDepartment of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, USA.ORCID 0000-0003-2479-5189
Venkatakrishna Rao JalaDepartment of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, USA.ORCID 0000-0002-4206-7305
University of Louisville · US

Funding

Understanding the Host-Microbiome-Therapeutic Triad: Implications for Designing Alternative IntravaginalP20GM125504 · NIGMS · UNIVERSITY OF LOUISVILLE · PI Shirin Ghods · 2018 to 2026
$24.4M
University of Louisville Center for Integrative Environmental Health SciencesP30ES030283 · NIEHS · UNIVERSITY OF LOUISVILLE · PI Amanda Jo LeBlanc · 2020 to 2026
$10.0M
Role of urolithin A in progression of alcohol-associated liver diseaseR21AA030638 · NIAAA · UNIVERSITY OF LOUISVILLE · PI JALA, VENKATAKRISHNA RAO · 2023 to 2024
$411k
NIAAA NIH HHS R21 AA030638NIEHS NIH HHS P30 ES030283NIGMS NIH HHS P20 GM125504
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bacterial ToxinsClostridioides difficileClostridium InfectionsColitisCoumarinsEnterocolitis, PseudomembranousAnimalsBacterial ProteinsEnterotoxinsMice3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-oneBacterial ProteinsBacterial ToxinsCoumarinsEnterotoxinsClostridioides difficilecolitisgut barrier functiontoxin productionurolithin A

Identifiers

PMID38193707
PMCPMC10878087
OpenAlexW4391109686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.